RenovoRx raises $11.1M via private placement of shares and warrants; funds Phase III trial into 2026

RenovoRx, Inc.

Gross proceeds of ~$11.1M from sale of 7,912,364 shares and warrants at $1.4075 per unit.
Warrants include Series A (5-year, $1.22 strike) and Series B (2-year, $1.22 strike), 150% warrant coverage.
Cash runway extended into 2026; combined with prior $6.1M Jan 2024 financing.
Proceeds fund pivotal Phase III TIGeR-PaC trial through second interim readout (est. late 2024).
Financing also enables expansion of TAMP clinical pipeline into additional cancer indications.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

RenovoRx, Inc. entered into Subscription Agreements with approximately 170 accredited investors (effective 2024-04-04).

Action: entry
Agreement: equity purchase
Counterparty: approximately 170 accredited investors
Effective: 2024-04-04

Exact text from the filing

On April 4, 2024, RenovoRx, Inc. (the “Company”) entered into a series of definitive subscription agreements (the “Subscription Agreements”) in connection with a private placement offering by the Company (the “Offering”) to approximately 170 accredited investors (the “Investors”).

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

RenovoRx, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-014069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.